Upstream Bio, Inc. (UPB) - Total Liabilities
Based on the latest financial reports, Upstream Bio, Inc. (UPB) has total liabilities worth $12.61 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Upstream Bio, Inc. to track the company's year-over-year net asset growth rate.
Upstream Bio, Inc. - Total Liabilities Trend (2022–2024)
This chart illustrates how Upstream Bio, Inc.'s total liabilities have evolved over time, based on quarterly financial data.
Upstream Bio, Inc. Competitors by Total Liabilities
The table below lists competitors of Upstream Bio, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
XinJiang Beiken Energy Engineering Stock Co Ltd
SHE:002828
|
China | CN¥1.16 Billion |
|
Okea ASA
OL:OKEA
|
Norway | Nkr1.96 Billion |
|
Hellenic Exchanges - Athens Stock Exchange SA
AT:EXAE
|
Greece | €494.17 Million |
|
STP&I Public Company Limited
BK:STPI
|
Thailand | ฿5.97 Billion |
|
Shenzhen King Brother Electronics Technology Co.Ltd.
SHE:301041
|
China | CN¥259.98 Million |
|
Jiangsu Aoyang Technology Ltd
SHE:002172
|
China | CN¥1.77 Billion |
|
Ashoka Buildcon Limited
NSE:ASHOKA
|
India | Rs64.74 Billion |
|
Fusion Micro Finance Limited
NSE:FUSION
|
India | Rs58.39 Billion |
Liability Composition Analysis (2022–2024)
This chart breaks down Upstream Bio, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see UPB market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 32.67 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.03 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Upstream Bio, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Upstream Bio, Inc. (2022–2024)
The table below shows the annual total liabilities of Upstream Bio, Inc. from 2022 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $11.87 Million | -95.06% |
| 2023-12-31 | $240.32 Million | +92.83% |
| 2022-12-31 | $124.63 Million | -- |
About Upstream Bio, Inc.
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporat… Read more